



T: 0131-244-2528
E: irene.fazakerley@gov.scot

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Medical Directors NHS Boards

5 February 2025

Dear Healthcare Professional,

DRUG ALERT CLASS 2 – No 5 2025 – CLASS 2 MEDICINES RECALL – ACTION WITHIN 48 HOURS – CNX THERAPEUTICS – NITROFURANTOIN 100MG PROLONGED-RELEASE CAPSULES

Please see drug alert for onward transmission as below

Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Primary Care Pharmacists

Please could Medical Directors arrange to forward this alert on to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY
Medicines Policy Team





MEDICINES RECALL

CLASS 2 MEDICINES RECALL, EL(25)A/05

Action within 48 hours

Distribute to Pharmacy/Wholesaler Level Recall

MEDICINE DETAILS

Nitrofurantoin CNX Therapeutics 100 mg Prolonged-Release capsules

PL: 19635/0006

Active Ingredient: nitrofurantoin

SNOMED code: 44125511000001105

MANUFACTURED BY

CNX Therapeutics Limited

AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
24849001	31/07/2026	14 capsules	13/12/2024
24849002	31/07/2026	14 capsules	13/12/2024

Background

CNX Therapeutics is recalling the above batches as a precautionary measure due to a small number of packs that contain an additional tablet of Nitrofurantoin. The registered product is a capsule containing powder and two yellow tablets. A small percentage of blister pockets have been found to contain an additional yellow tablet alongside the capsule, these are from the manufacturing process and not from broken capsules.



Advice for Healthcare Professionals:

Stop supplying the above listed batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

Should a patient present a pack containing an extra tablet, the tablet may be removed and the patient assured that the capsule is safe to take stating the extra tablet did not come from the capsule.

Advice for Patients:

If you find a pack containing an additional tablet, please take the medication to the dispensing pharmacy you obtained the medicine from. Patients may continue to take capsules from non-impacted packs as prescribed by your healthcare professional.

A small percentage of blister pockets have been found to contain an additional yellow tablet alongside the capsule, these are from the manufacturing process and not from broken capsules.

Patients that have taken the additional tablet with the capsule have ingested a higher dose of nitrofurantoin than was intended, however, the effects are understood and this should not have caused harm.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

Additional information:

For medical information enquiries please contact 0207 821 2840 or medinfo@cnx-therapeutics.com

For stock control enquiries please contact 0207 821 2840 or supplychain@cnx-therapeutics.com

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
DMRC@mhra.gov.uk